Abstract
AMSBIO
MagSi-NGSPREP for NGS
This magnetic bead-based tool for Next Generation Sequencing (NGS) applications supports all standard DNA clean-up protocols encountered during Next-Gen library preparation, including the classical one-sided and two-sided “solid phase reversible immobilization” (SPRI) size selection protocols. Protocols using MagSi-NGSPREP can be adjusted to specific applications and NGS platforms. MagSi-NGSPREP can be used manually but is also easy to automate for high-throughput processing.
Using MagSi-NGSPREP, DNA fragments are bound directly onto the surface of the magnetic beads, leaving unincorporated nucleotides, primers, primer dimers, and other contaminants in solution. Following this the DNA fragments are eluted with low salt buffer or reagent grade water. The technology for binding of DNA fragments onto the applied magnetic nanoparticle surface does not require use of any hazardous chaotropic buffers. The purification protocols are optimized to provide high yield and purity of the recovered DNA fragments.
MagSi-NGSPREP allows selective binding of DNA with a size cut-off between 100bp and 1kb with specific reagent volume: sample volume ratios. By increasing the volume of MagSi-NGSPREP, the efficiency of binding smaller fragments increases. This enables users to selectively keep or discard undesired fragment sizes. Depending on which protocol is used, total preparation time using MagSi-NGSPREP is 20-30 minutes and the hands-on time necessary for the whole procedure is reduced to a minimum. The kit is stable for 1 year when stored at 2-8°C.
More: www.amsbio.com/Next_Generation_Sequencing_Library.aspx
MagSi-Direct
MagSi-Direct provides a way to attach virtually any biomolecule to nanoscopic paramagnetic beads. It is considered well suited for exploiting interactions between a biomolecule and its binding partners. With MagSi-Direct, users begin with a molecule of interest, attach magnetic beads to it, and then use a magnet to isolate that molecule from any desired reaction mixture, together with any other molecules, complexes, or even intact cells to which the starting molecule has bound. In effect, the starting molecule is converted into a magnetic affinity reagent, or “bait,” which can be used to purify, isolate, or characterize the partners with which it interacts.
MagSi-Direct beads attach to the starting molecule via strong coordinate bonds between the surface of the bead and any electron donating group on the molecule. Molecular orientation is non-specific and random. Consequently, within a population of beads, all possible orientations of the starting molecule will be represented and available for interactions.
ATCC
Certified Reference Materials
Mycoplasma Quality Control Solutions with Quantitative Mycoplasma Genomic DNA now support ATCC’s range of quality control products, which include the Universal Mycoplasma Detection Kit and a collection of 10 titered mycoplasma reference strains. ATCC Certified Reference Materials are calibrated to one or more specified properties for use in challenge assays, verifying or comparing test methods, and benchmarking critical assay performance during assay validation or implementation.
These quantitative mycoplasma DNA Certified Reference Materials facilitate PCR-based detection of mycoplasma in cell culture, animal sera, and other raw materials. These nucleic acid preparations are isolated from strains most frequently associated with cell culture contamination, and are quantified for genome copy number using digital PCR-based technology.
More: www.atcc.org
Curetis
Unyvero i60 ITI Cartridge
This new Implant and Tissue Infection (ITI) cartridge was developed to rapidly identify more than 90 pathogens and more than 20 resistance markers common in eight clinical indications. According to Curetis, it has been CE-IVD marked following the successful completion of a CE performance evaluation study of more than 750 cartridges. Analytical sensitivity testing was conducted in 350 cartridges, while more than 400 cartridges were run with patient samples. Samples of various clinical indications were obtained for the trial, including periprosthetic joint infections, diabetic foot, catheters, surgical sites, skin and soft tissue and cardiology-related infections. The Unyvero system analyzed challenging native clinical sample types such as swabs, synovial fluid, sonication fluid, tissue and catheters. Among others, the i60 cartridge detected several key pathogens with sensitivities in the range between 75% to 100% at an overall panel sensitivity of 67% and panel specificity of 97.8% for the 81 analytes that have been successfully validated so far. The i60 cartridge also identified 147 clinically important pathogens not found by standard microbiology culture. In particular, in every second sonication fluid and every third synovial fluid sample, i60 detected pathogens missed by microbiology culture. Pathogens most often overlooked by culture, yet identified by i60, were Enterococcus sp., Finegoldia magna, Corynebacterium sp., Enterobacter cloacae, and Acinetobacter baumannii. Resolution of discrepant results is ongoing.
Heraeus Medical is the development and commercialization partner for the Unyvero i60 ITI Cartridge.
More: www.curetis.com
Fluxion Biosciences
IsoFlux NGS Assay Kits for Circulating Biomarker Detection
IsoFlux NGS Assay Kits are designed to enhance and complete the workflow for next-generation sequencing (NGS). They work with circulating tumor material enriched on the IsoFlux System to increase the overall target purity of samples and provide a robust nucleic acid extraction method that is optimized for NGS. The kits incorporate a proprietary method of purity enhancement that, when combined with the IsoFlux System for primary enrichment, deliver a high purity DNA or RNA sample immediately ready for NGS. The kits have been developed and validated with leading commercial NGS platforms and cancer mutation panels ranging from 5 to 500 genes of interest to cancer.
Oxford Gene Technology (OGT)
SureSeq Solid Tumour Panel
Fully validated on formalin-fixed, paraffin-embedded (FFPE) samples, the new 60-gene next generation sequencing (NGS) hybridization-based enrichment panel offers accurate and reliable solid tumor profiling for both known and novel variants. The content of the panel has been defined by recognized cancer experts, covering key genes for a range of cancer types including breast, prostate, ovarian, lung and colorectal. All exons of these genes are fully covered, including mutation hotspots, enabling both detection and discovery of known and novel variants respectively.
According to OGT, the hybridization-based SureSeq Solid Tumour Panel minimizes PCR bias and duplications commonly associated with alternative enrichment methodologies, enabling greater run-to-run consistency. OGT’s expert bait design ensures uniform and sensitive enrichment by providing efficient and improved uniformity of coverage of the targeted regions, enabling all variants to be called with maximum confidence.
The SureSeq Solid Tumour Panel comes with OGT’s Variant Analysis Report, enabling users to explore and retrospectively interrogate data with additional or new selection criteria, without the need for additional in-house bioinformatics resources. Using the report, data can be easily filtered by numerous parameters, including gene, depth of coverage, somatic variants and predicted effect on the protein. In addition, all variants are fully annotated with links to various databases.
More: http://www.ogt.com/products/915_sureseq_solid_tumour_panel
Porvair Sciences
ChIP Sequencing Kit for Next Generation Sequencing
Designed to extend the benefits of Porvair’s Chromatrap solid state ChIP technology to preparation of purified chromatin for the next generation of sequencing libraries, this chromatin immunoprecipitation (ChIP) sequencing assay kit combines Chromatrap’s range with the downstream analysis power of deep sequencing, allowing the genome-wide identification of transcription factor binding sites and specific DNA associated protein modifications with no limitation in scale and resolution.
More: www.porvair-sciences.com
QIAGEN
GeneRead DNAseq V2 Gene Panels
Fourteen new GeneRead DNAseq V2 Gene Panels are now available for enriching genes of interest in samples prior to next-generation sequencing (NGS) runs. According to QIAGEN, these panels can be seen as the core assay in the workflow. They are customizable to include other genes or gene regions of interest, are compatible with any NGS sequencer and are part of QIAGEN’s sample-to-library workflows.
The 14 new GeneRead DNAseq V2 panels target a range of cancer-related genes and gene regions, including “focused” panels each targeting 8-25 genes, “disease-specific” panels for 40-50 genes, and “comprehensive” panels for as many as 160 genes. The content of the panels has been developed based on the recommendations from relevant medical and scientific literature. The gene panels are integrated with QIAGEN’s bioinformatics software, Ingenuity Variant Analysis, a database of gene variants and clinical data that enables interpretation of NGS results and provides insight from sequencing data. Laboratories also can customize GeneRead panels for specific disease pathways or research needs by tapping into QIAGEN’s deep molecular content portfolio through GeneGlobe, an online portal covering more than 60,000 annotated molecular assays.
GeneRead panels use as little as 10 nanograms of starting DNA material per pool. They are compatible with FFPE samples and do not require any specialized instruments. The proprietary algorithms and chemistry provide coverage (>96% of coding regions), specificity (>90% of reads on target) and uniformity (>90% of bases are covered by at least 20% of the mean coverage depth) for the targeted DNA sequencing. In addition, QIAGEN gene panels require only three hours to enrich for targets and provide for a reduced time to go from isolated DNA sample to sequencing-ready libraries.
More: www.qiagen.com
SeraCare Life Sciences
ACCURUN HPV mRNA Positive and Ct/Ng Negative Controls
The ACCURUN 381 HPV Type 16 and 18 mRNA Positive Controls include the full length episomal genome and targets RNA-based assays. This product is manufactured from cultured human cells infected with HPV Type 16 or Type 18 that have integrated into the cellular genome. The cells bear the mRNA transcribed from the viral genes and are preserved in a buffered methanol solution. The control is ready to use in assays that detect high risk HPV mRNA of E6 and E7 viral genes.
The ACCURUN 841 Chlamydia trachomatis Neisseria gonorrhea Negative Control is formulated for use with in vitro diagnostic amplified test methods that detect Chlamydia trachomatis Neisseria gonorrhea nucleic acid. This product is manufactured in a proprietary buffer simulating specimen transport media that contains the human cellular components required to obtain valid negative results on assay platforms. The Ct/Ng negative control closely mimics human samples as a result of its whole organism design.
More: www.seracare.com
Ventana Medical Systems
Companion RPAs for Biomarkers PSMA, MDM2 and FGFR
Three new companion diagnostic robust prototype assays (RPAs) for the detection of biomarkers PSMA (prostate specific membrane antigen), MDM2 ISH (mouse double minute 2) and FGFR2 (fibroblast growth factor receptor 2) bring Ventana’s CAP/CLIA testing menu to almost 400, nearly 100 of which are RPA assays and the remainder are IVD approved Ventana tests. These robust prototype assays are in vitro diagnostic tests used in biomarker identification and have been validated, manufactured and used within a single clinical laboratory. The Ventana CAP/CLIA lab is a full-service histopathology lab that employs automated staining platforms and validated assays for IHC and ISH staining of retrospective and prospective clinical samples.
More: www.ventana.com
W. R. Grace & Co.
ProVance Pre-Packed Protein A Columns
According to W.R. Grace & Co., ProVance columns are a high-performance disposable chromatography solution for downstream purification. They combine Grace proprietary incompressible silica with cost-effective Protein A and disposable column hardware. The high capacity columns can reduce operating costs by 40-60 percent and are considered ideally suited for single-batch or single-campaign use eliminating the need for significant cleaning validations and long-term storage.
ProVance columns are available in a range of sizes for early screening and up to full-scale GMP manufacturing. Columns for use in GMP manufacturing come complete with documentation for regulatory support, shipping studies, and leachables, and extractables.
More: www.grace.com/provance
About JALA World News:
E-mail new product announcements for consideration to